Objective To investigate the expression and clinical significance of BRMS1 ( breast cancer metastasis suppressorl ) protein in colon cancer.Methods The expression of BRMS1 protein was detected by using EliVision immunohistochemical techniques in 46 cases of colon cancer,and adjacent non cancerous colon tissues.The clinical significance with histopathologic records was aralyzed.Results The expression levels of BRMS1 ( 34.8％ ) in the colon cancer tissues was significantly lower than those of adjacent non cancerous colon tissues( x2 =23.92,P ＜0.01 ).The expression of BRMSl was significantly correlated with tumor size,clinical stage,and lymph node status (x2 =6.02,4.28,4.35,all P＜0.01) ;BRMS1 had no correlation with age,pathological type.Conclusion BRMS1 might synergistically promote the metastasis of colon cancer.Detection of the expression of BRMS1 may be hdpful in determineing the prognosis of colon cancer.

Cerebellar Neoplasms ; diagnosis ; pathology ; radiotherapy ; surgery ; Follow-Up Studies ; Humans ; Infant ; Magnetic Resonance Imaging ; Male ; Medulloblastoma ; diagnosis ; pathology ; radiotherapy ; surgery

Castleman Disease ; complications ; metabolism ; pathology ; surgery ; Dendritic Cell Sarcoma, Follicular ; complications ; metabolism ; pathology ; surgery ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Receptors, Complement 3b ; metabolism ; Thoracic Diseases ; complications ; metabolism ; pathology ; surgery ; Thoracic Wall ; Vimentin ; metabolism

BACKGROUND: Early withdrawal of invasive mechanical ventilation (IMV) followed by noninvasive MV (NIMV) is a new strategy for changing modes of treatment in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) with acute respiratory failure (ARF). Using pulmonary infection control window (PIC window) as the switch point for transferring from invasive to noninvasive MV, the time for early extubation can be more accurately judged, and therapy efficacy can be improved. This study aimed to prospectively investigate the clinical effectiveness of fiberoptic bronchscopy (FOB) in patients with AECOPD during sequential weaning of invasive-noninvasive MV. METHODS: Since July 2006 to January 2011, 106 AECOPD patients with ARF were treated with comprehensive medication and IMV after hospitalization. Patients were randomly divided into two groups according to whether fiberoptic bronchoscope is used (group A, n=54) or not (group B, n=52) during sequential weaning from invasive to noninvasive MV. In group A, for sputum suction and bronchoalveolar lavage (BAL), a fiberoptic bronchoscope was put into the airway from the outside of an endotracheal tube, which was accompanied with uninterrupted use of a ventilator. After achieving PIC window, patients of both groups changed to NIMV mode, and weaned from ventilation. The fol owing listed indices were used to compare between the groups after treatment: 1) the occurrence time of PIC, the duration of MV, the length of ICU stay, the success rate of weaning from MV for the first time, the rate of reventilation and the occurrence rate of ventilator-associated pneumonia (VAP); 2) the convenience and safety of FOB manipulation. The results were compared using Student's t test and the Chi-square test. RESULTS: The occurrence time of PIC was (5.01±1.49) d, (5.87±1.87) d in groups A and B, respectively (P<0.05); the duration of MV was (6.98±1.84) d, (8.69±2.41) d in groups A and B, respectively (P<0.01); the length of ICU stay was (9.25±1.84) d, (11.10±2.63) d in groups A and B, respectively (P<0.01); the success rate of weaning for the first time was 96.30％, 76.92％ in groups A and B, respectively (P<0.01); the rate of reventilation was 5.56％, 19.23％ in groups A and B, respectively (P<0.05); and the occurrence rate of VAP was 3.70％, 23.07％ in groups A and B, respectively (P<0.01). Moreover, it was easy and safe to manipulate FOB, and no side effect was observed. CONCLUSIONS: The application of FOB in patients with AECOPD during sequential weaning of invasive-noninvasive MV is effective in ICU. It can decrease the duration of MV and the length of ICU stay, increase the success rate from weaning MV for the first time, reduce the rate of reventilation and the occurrence rate of VAP. In addition, such a method is convenient and safe in patients of this kind.

Air ; analysis ; Alcohols ; analysis ; Electrophoresis, Capillary ; Workplace

BACKGROUND: Existing flaws have been found in the production process of poly(lactic-co-glycolic acid) (PLGA) copolymer microspheres, which lead to residual solvent, low drug loading rate and low encapsulation efficiency of sustained-release microspheres.OBJECTIVE: To review different methods for preparing PLGA microspheres from the following aspects: basic principles, advantages/disadvantages, indications and future development. METHODS: We retrieved CNKI, PubMed and Google scholar to access the articles related to the technique process of preparing PLGA microspheres published from January 2012 to April 2017, including experiment and application research on the principles and advantages/disadvantages of the various processes. RESULTS AND CONCLUSION: To date, the main methods to prepare PLGA microspheres include single/re-emulsion solvent evaporation method, spray drying method, hydrogel template method, microfluid, coaxial electrostatic spraying, phase separation method, and supercritical fluid extraction. However, no valid evidences suggest that there is a technique that completely solves all potential problems, such as drug encapsulation and release, residual solvent and appropriate shape and size. Combination and modification of the production processes is expected to develop novel PLGA microspheres with ideal encapsulation efficiency and stable drug release.

OBJECTIVETo construct a recombinant lentivirus vector containing fusion gene NT4-p53(N15)-Ant and transfer it into HepG2 cancer cells for gene therapy.

METHODSThe gene of p53(N15)-Ant was obtained by T-vector method. After restriction enzyme digestion, the interest gene of p53(N15)-Ant was inserted in pBV220/NT4 vector and fusion gene of NT4-p53(N15)-Ant was subcloned into the plasmid of lentivirus and cotransferred into HEK-293 cells with helper plasmid. The recombinant lentivirus was produced by homologous recombination of the above mentioned two plasmids in HEK-293 cells and its titer was measured by plaque-forming. The expression of LV. NT4-p53-Ant in transfected HepG2 cells was finally confirmed by reverse transcription polymerase chain reaction (RT-PCR) procedure. The effect of LV. NT4-p53(N15)-Ant on HepG2 cells was measured by a colorimetric 3-[4,5-dimethyl thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. The inhibition effect on HepG2 cells of LV. NT4-p53(N15)-Ant and its potential mechanism was detected by light microscopy, electron microscopy, MTT, LDH-release assay and annexin V-PI double staining.

RESULTSThe gene of p53(N15)-Ant was confirmed by restriction enzyme digestion and DNA sequencing. High titer of the recombinant lentivirus was obtained by homologous recombination in HEK-293 cell lines (1 x 10(11) pfu/ml), and the expression of NT4-p53(N15)-Ant gene in HepG2 cells was confirmed by RT-PCR. The viability of HepG2 cells was decreased to 83.4%, 46.9% and 33.9%, at 24 h, 48 h and 72 h, respectively, after infection by LV. NT4-p53(N15)-Ant. Compared with the LV. EGFP control group, there were significant differences (P < 0.01). The LDH level in HepG2 cells infected by LV. NT4-p53(N15)-Ant at 48 h, 72 h and 96 h after infection was 682 IU/L, 815 IU/L and 979 IU/L, respectively, significantly increased than that in the LV. EGFP group (P < 0.01), indicating the cell membrane destruction.

CONCLUSIONThe recombinant lentivirus vector encoding gene NT4-p53(N15)-Ant is successfully constructed in this experiment by molecular cloning and recombination in vitro techniques, and the results suggested that this fusion gene has an anti-tumor effect, which provides the basis for further research on recombinant adenovirus for cancer gene therapy.

Cell Survival ; Genetic Therapy ; Genetic Vectors ; HEK293 Cells ; Hep G2 Cells ; Humans ; L-Lactate Dehydrogenase ; metabolism ; Lentivirus ; genetics ; metabolism ; Nerve Growth Factors ; genetics ; metabolism ; Nucleotide Transport Proteins ; genetics ; metabolism ; Plasmids ; Recombinant Fusion Proteins ; genetics ; metabolism ; Transfection ; Tumor Suppressor Protein p53 ; genetics ; metabolism

Objective To observe the clinical efficacy ofChanhou Fujiu decoction plus acupuncture-moxibustion in preventing and treating incomplete drug abortion.Method A total of 204 patients in early-stage pregnancy asking for drug abortion were randomized into group A, group B, and group C, 68 cases in each group. Group A was given oral administration of Mifeprostone and Misoprostol tablets, plus Azithromycin dispersible tablet for prevention of infection. Group B was intervened by orally takingChanhou Fujiu decoction in addition to the treatment given to group A. Group C was intervened by acupuncture-moxibustion therapy based on the treatment given to group B. The vaginal bleeding time and amount, and the recovery of menstruation in the three groups were observed after the intervention, and the clinical efficacies were compared.Result Compared with group A, the vaginal bleeding amount after drug abortion was significantly smaller (P<0.05), the bleeding duration were significantly shorter (P<0.05), and time taken for the recovery of menstruation was markedly shorter (P<0.05) in group B and C, and there were no significant abnormal conditions in the menstrual periods (P>0.05). Compared with group B, group C had significantly smaller amount of vaginal bleeding (P<0.05) and shorter duration of vaginal bleeding (P<0.05), and there were no significant abnormal conditions in the time taken for the recovery of menstruation and menstrual periods (P>0.05). The total effective rate was 75.0％ in group B and 95.6％ in group C, both significantly higher than 58.8％ in group A (P<0.05), and the total effective rate in group C was markedly higher than that in group B (P<0.05). Conclusion Chanhou Fuyuan decoction plus acupuncture-moxibustion can effectively prevent and treat complications of drug abortion, and is an effective method in preventing and treating incomplete drug abortion.

To study the molecular mechanisms of nitric oxide donor sodium nitroprusside (SNP) -induced apoptosis in K562 human leukemia cell line, the different concentrations of SNP and different time of culture were used to treat K562 cell. At the same time, potassium ferricyamide (PFC) was used as control, blank was designed in experiment. Cell apoptosis was analysed by cell morphology, DNA agarose gel electrophoresis, DNA content, and annexin-V/PI labeling method. The TdT-mediated dUTP nick end labeling (TUNEL) assay was used to quantify in situ cell apoptosis. Reactive oxygen species (ROS) in cells and mitochondrial transmembrane potential (DeltaPsim) were labeled by dihydrorhodamin 123, 2', 7'-dichlorodihydrofluorescein diacetate and rhodamin 123/PI. bcl-2, bax, bad, p53 gene proteins and mitochondrial membrane protein were analysed by flow cytometry. The results showed that the K562 cell apoptosis was confirmed by typical cell morphology, DNA fragment, sub-G(1) phase, TUNEL and annexin-V/PI labeling. A majority of K562 cells were arrested in G(0)/G(1) phase. During the process of SNP-induced apoptosis in K562 cell, the mean fluorescence intensity of ROS in cells was significantly higher than those in blank and PFC control, while the DeltaPsim reduced. The expression of p53, bax, bad, Fas protein and mitochondrial membrane protein increased and bcl-2 protein decreased after SNP treatment. It is concluded that SNP induces K562 cell apoptosis through increasing ROS in cells, expressing the p53, bax, bad, Fas protein and mitochondrial membrane protein and decreasing bcl-2 protein, opening the mitochondrial permeability transition pore and reducing DeltaPsim. Furthermore, the Fas was activated during the apoptosis process.
Apoptosis ; drug effects ; Dose-Response Relationship, Drug ; Humans ; In Situ Nick-End Labeling ; K562 Cells ; Membrane Potential, Mitochondrial ; drug effects ; Nitric Oxide Donors ; pharmacology ; Nitroprusside ; pharmacology ; Proto-Oncogene Proteins c-bcl-2 ; metabolism ; Reactive Oxygen Species ; metabolism ; Tumor Suppressor Protein p53 ; metabolism ; bcl-2-Associated X Protein ; metabolism ; fas Receptor ; biosynthesis

OBJECTIVETo assess whether the existing three types of pharmacogenetics-based Warfarin dosing algorithms appropriately predict the actual maintenance dose in Han Chinese mechanical heart valve replacement patients (n = 130).

METHODSThe patients' CYP2C9 and VKORC1 genetic polymorphisms were detected by PCR-RFLP. The genotype of CYP2C9, VKORC1 and other information were used to calculate predicted doses. Accuracy of the models was assessed using the absolute value of the difference between predicted dose and actual dose, calculated on both an absolute and percentage basis. Actual weekly dose was also regressed on predicted weekly dose, from which we obtained R(2) values. Clinical accuracy of the predictions was assessed by computing the proportion in which the predicted dose was 20% or more below the actual dose (under dosed), within 20% of the actual dose (ideally dosed), or 20% or greater above the actual dose (over dosed).

RESULTSThe average absolute error is the smallest for the predictions made by the Wen model (3.74 mg/wk), followed by the Ohno model (4.07 mg/wk) and IWPC model (5.05 mg/wk). R(2) was 40.2% in the Wen model, 38.2% in the Ohno model and 26.7% in the IWPC model. When comparing the percentage of patients for whom the predicted doses were ideal, the Wen model works the best (50.0%) in low-dose group (≤ 21 mg/wk), but the Ohno model works the best (85.29%) in middle-dose group (21 - 49 mg/wk), followed by the Wen model.

CONCLUSIONThe best accuracy is achieved by the Wen model and the best clinical accuracy is obtained by the Ohno model for predicting the actual maintenance dose in Han Chinese mechanical heart valve replacement patients.

Adolescent ; Adult ; Aged ; Anticoagulants ; administration & dosage ; Aryl Hydrocarbon Hydroxylases ; genetics ; Asian Continental Ancestry Group ; genetics ; Cytochrome P-450 CYP2C9 ; Drug Design ; Female ; Genotype ; Humans ; Male ; Middle Aged ; NAD(P)H Dehydrogenase (Quinone) ; genetics ; Pharmacogenetics ; Polymorphism, Genetic ; Warfarin ; administration & dosage ; Young Adult